Inhibikase Therapeutics Management
Management criteria checks 3/4
Inhibikase Therapeutics' CEO is Milton Werner, appointed in Jun 2010, has a tenure of 13.75 years. total yearly compensation is $744.06K, comprised of 67.3% salary and 32.7% bonuses, including company stock and options. directly owns 14.37% of the company’s shares, worth $1.98M. The average tenure of the management team and the board of directors is 9.4 years and 3.3 years respectively.
Key information
Milton Werner
Chief executive officer
US$744.1k
Total compensation
CEO salary percentage | 67.3% |
CEO tenure | 13.8yrs |
CEO ownership | 14.4% |
Management average tenure | 9.4yrs |
Board average tenure | 3.3yrs |
Recent management updates
Recent updates
Can Inhibikase Therapeutics (NASDAQ:IKT) Afford To Invest In Growth?
Jan 25Inhibikase stock rises 12% on FDA nod to start study of IkT-001Pro for leukemia
Aug 26Inhibikase Therapeutics GAAP EPS of -$0.18, revenue of $6.55M
Aug 12Will Inhibikase Therapeutics (NASDAQ:IKT) Spend Its Cash Wisely?
Aug 09Here's Why We're Watching Inhibikase Therapeutics' (NASDAQ:IKT) Cash Burn Situation
Apr 06Inhibikase Therapeutics prices stock offering at $3
Jun 16CEO Compensation Analysis
Date | Total Compensation | Salary | Company Earnings |
---|---|---|---|
Sep 30 2023 | n/a | n/a | -US$19m |
Jun 30 2023 | n/a | n/a | -US$19m |
Mar 31 2023 | n/a | n/a | -US$18m |
Dec 31 2022 | US$744k | US$501k | -US$18m |
Sep 30 2022 | n/a | n/a | -US$19m |
Jun 30 2022 | n/a | n/a | -US$19m |
Mar 31 2022 | n/a | n/a | -US$17m |
Dec 31 2021 | US$611k | US$455k | -US$15m |
Sep 30 2021 | n/a | n/a | -US$11m |
Jun 30 2021 | n/a | n/a | -US$7m |
Mar 31 2021 | n/a | n/a | -US$5m |
Dec 31 2020 | US$961k | US$293k | -US$3m |
Sep 30 2020 | n/a | n/a | -US$2m |
Jun 30 2020 | n/a | n/a | -US$3m |
Mar 31 2020 | n/a | n/a | -US$5m |
Dec 31 2019 | US$385k | US$293k | -US$6m |
Sep 30 2019 | n/a | n/a | -US$7m |
Mar 31 2019 | n/a | n/a | -US$4m |
Dec 31 2018 | US$535k | US$452k | -US$2m |
Compensation vs Market: Milton's total compensation ($USD744.06K) is about average for companies of similar size in the US market ($USD661.05K).
Compensation vs Earnings: Milton's compensation has increased whilst the company is unprofitable.
CEO
Milton Werner (59 yo)
13.8yrs
Tenure
US$744,055
Compensation
Dr. Milton H. Werner, Ph D., serves as the Chief Executive Officer and President at Inhibikase Therapeutics, Inc. since June 2010. Prior to founding Inhibikase, From May 2007 until August 2008, Dr. Werner...
Leadership Team
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
CEO, President & Director | 13.8yrs | US$744.06k | 14.37% $ 2.0m | |
Chief Financial Officer | 5.9yrs | US$574.77k | 0.011% $ 1.5k | |
Head of Preclinical Research | 9.2yrs | no data | no data | |
Head of Chemistry | 9.6yrs | no data | no data | |
CEO of Clintrex Research Corporation & Member of Scientific Advisory Board | no data | no data | no data | |
Controller | no data | no data | no data |
9.4yrs
Average Tenure
Experienced Management: IKT's management team is seasoned and experienced (9.4 years average tenure).
Board Members
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
CEO, President & Director | 13.8yrs | US$744.06k | 14.37% $ 2.0m | |
CEO of Clintrex Research Corporation & Member of Scientific Advisory Board | no data | no data | no data | |
Independent Director | 3.3yrs | US$84.62k | 0% $ 0 | |
Independent Director | 3.3yrs | US$78.62k | 0% $ 0 | |
Member of Scientific Advisory Board | no data | no data | no data | |
Member of Scientific Advisory Board | no data | no data | no data | |
Independent Director | 3.3yrs | US$69.62k | 0% $ 0 | |
Member of Scientific Advisory Board | no data | no data | no data | |
Member of Scientific Advisory Board | no data | no data | no data | |
Independent Director | 1.5yrs | US$58.89k | no data | |
Member of Scientific Advisory Board | no data | no data | no data | |
Member of Scientific Advisory Board | no data | no data | no data |
3.3yrs
Average Tenure
65yo
Average Age
Experienced Board: IKT's board of directors are considered experienced (3.3 years average tenure).